SequelSEC

MANGOCEUTICALS, INC. MGRX

Services-Misc Health & Allied Services, NEC · CIK 0001938046 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$456.02K
Fiscal year ended 2025-12-31
Operating income
-$18.03M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

MANGOCEUTICALS, INC. (MGRX) reported revenue of $456.02K and net income of -$20.64M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from MANGOCEUTICALS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Misc Health & Allied Services, NEC.

Income

MANGOCEUTICALS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Revenue$456.02K$615.87K$731.49K$8.94K
Cost of revenueUnavailableUnavailableUnavailable$4.09K
Gross profitUnavailableUnavailableUnavailable$4.85K
Operating income-$18.03M-$7.97M-$9.22M-$1.99M
Net income-$20.64M-$8.71M-$9.21M-$2.00M
Research & developmentUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 10.07Mshares 1.98Mshares 1.07Mshares 10.80M
Pretax income-$20.64M-$8.71M-$9.21M-$2.00M
Income tax expenseUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-2.17$-4.80$-8.58$-0.19
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$3.76M$3.00M$3.32M$1.64M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

MANGOCEUTICALS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Cash & equivalents$1.49M$58.65K$739.01K$682.86K
Total assets$16.09M$15.37M$1.05M$1.00M
Current assets$1.55M$75.60K$835.40K$694.60K
Total liabilities$890.57K$1.43M$276.04K$389.26K
Current liabilities$890.57K$1.43M$211.08K$260.58K
Total equity incl. NCI$15.20M$13.95M$774.75K$614.03K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailable$18.50KUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailable

Cash flow

MANGOCEUTICALS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Operating cash flow-$5.85M-$4.86M-$7.00M-$1.35M
Capital expendituresUnavailableUnavailable$3.52K$43.10K
Investing cash flowUnavailable$65.00K-$3.52K-$43.10K
Financing cash flow$7.27M$4.13M$7.06M$2.05M
Net change in cashUnavailableUnavailable$56.15K$660.31K
Stock-based compensation$1.17M$248.68K$624.46K$234.09K
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailable$9.94K$24.89KUnavailable

Derived

MANGOCEUTICALS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Free cash flowUnavailableUnavailable-$7.00M-$1.39M
Gross margin54.9%61.7%59.0%54.3%
Operating margin-3954.3%-1294.4%-1260.3%-22279.7%
FCF marginUnavailableUnavailable-957.1%-15545.6%
SBC / revenue256.2%40.4%85.4%2618.7%
Current ratio1.74x0.05x3.96x2.67x
Revenue YoY growth-26.0%-15.8%8083.2%Unavailable
Net margin-4526.8%-1413.6%-1259.4%-22352.1%
R&D / revenueUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailable0.5%482.2%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MGRX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-19View SEC filing
10-K · Filed 2026-04-01View SEC filing
10-Q/A · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing

Companies in the same industry

AGL BRTX CCEL DVA MRAI PARK PFHO PGNY SHC VMD

Reconciliation checks needing review

3 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2025-12-31

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-12-31

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-12-31

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.